OBJECTIVE: To examine the value of individual and combinations of ovarian cancer associated blood biomarkers for the discrimination between plasma of patients with type I or II ovarian cancer and disease-free volunteers. METHODS: Levels of 14 currently promising ovarian cancer-related biomarkers, including CA125, macrophage inhibitory factor-1 (MIF-1), leptin, prolactin, osteopontin (OPN), insulin-like growth factor-II (IGF-II), autoantibodies (AAbs) to eight proteins: p53, NY-ESO-1, p16, ALPP, CTSD, B23, GRP78, and SSX, were measured in the plasma of 151 ovarian cancer patients, 23 with borderline ovarian tumors, 55 with benign tumors and 75 healthy controls. RESULTS: When examined individually, seven candidate biomarkers (MIF, Prolactin, CA-125, OPN, Leptin, IGF-II and p53 AAbs) had significantly different plasma levels between type II ovarian cancer patients and healthy controls. Based on the receiver operating characteristic (ROC) curves constructed and area under the curve (AUC) calculated, CA125 exhibited the greatest power to discriminate the plasma samples of type II cancer patients from normal volunteers (AUC 0.9310), followed by IGF-II (AUC 0.8514), OPN (AUC 0.7888), leptin (AUC 0.7571), prolactin (AUC 0.7247), p53 AAbs (AUC 0.7033), and MIF (AUC 0.6992). p53 AAbs levels exhibited the lowest correlation with CA125 levels among the six markers, suggesting the potential of p53 AAbs as a biomarker independent of CA125. Indeed, p53 AAbs increased the AUC of ROC curve to the greatest extent when combining CA125 with one of the other markers. At a fixed specificity of 100%, the addition of p53 AAbs to CA125 increased sensitivity from 73.8% to 85.7% to discriminate type II cancer patients from normal controls. Notably, seropositivity of p53 AAbs is comparable in type II ovarian cancer patients with negative and positive CA125, but has no value for type I ovarian cancer patients. CONCLUSIONS: p53 AAbs might be a useful blood-based biomarker for the detection of type II ovarian cancer, especially when combined with CA125 levels.
OBJECTIVE: To examine the value of individual and combinations of ovarian cancer associated blood biomarkers for the discrimination between plasma of patients with type I or II ovarian cancer and disease-free volunteers. METHODS: Levels of 14 currently promising ovarian cancer-related biomarkers, including CA125, macrophage inhibitory factor-1 (MIF-1), leptin, prolactin, osteopontin (OPN), insulin-like growth factor-II (IGF-II), autoantibodies (AAbs) to eight proteins: p53, NY-ESO-1, p16, ALPP, CTSD, B23, GRP78, and SSX, were measured in the plasma of 151 ovarian cancerpatients, 23 with borderline ovarian tumors, 55 with benign tumors and 75 healthy controls. RESULTS: When examined individually, seven candidate biomarkers (MIF, Prolactin, CA-125, OPN, Leptin, IGF-II and p53 AAbs) had significantly different plasma levels between type II ovarian cancerpatients and healthy controls. Based on the receiver operating characteristic (ROC) curves constructed and area under the curve (AUC) calculated, CA125 exhibited the greatest power to discriminate the plasma samples of type II cancerpatients from normal volunteers (AUC 0.9310), followed by IGF-II (AUC 0.8514), OPN (AUC 0.7888), leptin (AUC 0.7571), prolactin (AUC 0.7247), p53 AAbs (AUC 0.7033), and MIF (AUC 0.6992). p53 AAbs levels exhibited the lowest correlation with CA125 levels among the six markers, suggesting the potential of p53 AAbs as a biomarker independent of CA125. Indeed, p53 AAbs increased the AUC of ROC curve to the greatest extent when combining CA125 with one of the other markers. At a fixed specificity of 100%, the addition of p53 AAbs to CA125 increased sensitivity from 73.8% to 85.7% to discriminate type II cancerpatients from normal controls. Notably, seropositivity of p53 AAbs is comparable in type II ovarian cancerpatients with negative and positive CA125, but has no value for type I ovarian cancerpatients. CONCLUSIONS:p53 AAbs might be a useful blood-based biomarker for the detection of type II ovarian cancer, especially when combined with CA125 levels.
Authors: David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum Journal: Am J Surg Pathol Date: 2007-02 Impact factor: 6.394
Authors: Yongliang Li; Antti Karjalainen; Heikki Koskinen; Kari Hemminki; Harri Vainio; Michael Shnaidman; Zhiliang Ying; Eero Pukkala; Paul W Brandt-Rauf Journal: Int J Cancer Date: 2005-03-10 Impact factor: 7.396
Authors: Ann K Folkins; Elke A Jarboe; Aasia Saleemuddin; Yonghee Lee; Michael J Callahan; Ronny Drapkin; Judy E Garber; Michael G Muto; Shelley Tworoger; Christopher P Crum Journal: Gynecol Oncol Date: 2008-03-14 Impact factor: 5.482
Authors: Miyun Tsai-Turton; Antonio Santillan; Dan Lu; Robert E Bristow; Kwun C Chan; Ie-Ming Shih; Richard B S Roden Journal: Gynecol Oncol Date: 2009-04-26 Impact factor: 5.482
Authors: E Stockert; E Jäger; Y T Chen; M J Scanlan; I Gout; J Karbach; M Arand; A Knuth; L J Old Journal: J Exp Med Date: 1998-04-20 Impact factor: 14.307
Authors: Tess V Clendenen; Alan A Arslan; Anna E Lokshin; Mengling Liu; Eva Lundin; Karen L Koenig; Franco Berrino; Goran Hallmans; Annika Idahl; Vittorio Krogh; Annekatrin Lukanova; Adele Marrangoni; Paola Muti; Brian M Nolen; Nina Ohlson; Roy E Shore; Sabina Sieri; Anne Zeleniuch-Jacquotte Journal: Cancer Causes Control Date: 2013-02-03 Impact factor: 2.506
Authors: Xiaoxiang Chen; Jing Zhang; Wenjun Cheng; Doo Young Chang; Jianfei Huang; Xuan Wang; Lizhou Jia; Daniel G Rosen; Wei Zhang; Da Yang; David M Gershenson; Anil K Sood; Robert C Bast; Jinsong Liu Journal: Int J Gynecol Cancer Date: 2013-06 Impact factor: 3.437
Authors: J W Pedersen; A Gentry-Maharaj; E-O Fourkala; A Dawnay; M Burnell; A Zaikin; A E Pedersen; I Jacobs; U Menon; H H Wandall Journal: Br J Cancer Date: 2012-11-20 Impact factor: 7.640
Authors: Cassandra A Hathaway; Megan S Rice; Mary K Townsend; Susan E Hankinson; Alan A Arslan; Julie E Buring; Göran Hallmans; Annika Idahl; Laura D Kubzansky; I-Min Lee; Eva A Lundin; Patrick M Sluss; Anne Zeleniuch-Jacquotte; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-07-08 Impact factor: 4.254